A clinical stage biotech company focusing on cell energy metabolism 

Mitochondrial biogenesis, lysosomal biogenesis, lysosomal acidification, and enhanced 
autophagy by upregulation of PGC-1a, TFEB and TRPML1
Small molecules T-168 and T-621 for oral administration
 → T-168 is in clinical phase 2 
 → T-621 is in IND enabling studies    
Our MOA is relevant across a broad range of indications in neuro, metabolic, 
cardiovascular, liver, kidney, and muscle diseases.

We are actively seeking pharma partners and early-stage investors to unlock the
broad potential of PGC-1α up-regulation in neurodegeneration and other disease areas.

Parkinson's disease, ALS, Mitochondria, lysosome, rare disease, cell energy, PGC-1a, TFEB. Phase 2 clinical trial, clinical stage. Partnering opportunity. Small molecules.

LEADERSHIP
Frederic Godderis, MS → founder | ceo | director
Enchi Liu, PhD → co-founder | chief development officer
Andrew Lam, MS → co-founder | chief technology officer
Saira Ramasastry, MS → corporate development lead

ADVISORS
Edgar Engleman, MD, PhD → scientific founder | Prof. of Pathology and Medicine | Vivo Capital | Stanford University, USA
Charalampos Tzoulis, MD, PhD → Prof. of Neurology & Neurogenetics | University of Bergen, Norway
Sanjay Kakkar, MD → founder | director | former chairperson of Tranquis Therapeutics and ceo of Tensive SRL | Milan, Italy